1.
Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin
VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE,
Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su
SM, Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature
462, 739-44 (2009).
2.
Yang H, Ye D, Guan KL, Xiong Y, IDH1 and IDH2 mutations in tumorigenesis:
mechanistic insights and clinical perspectives. Clin Cancer Res 18, 5562-71
(2012).
3.
Dang L, Yen K, Attar EC, IDH mutations in cancer and progress toward
development of targeted therapeutics. Ann Oncol 27, 599-608 (2016).
4.
Tommasini-Ghelfi S, Murnan K, Kouri FM, Mahajan AS, May JL, Stegh AH,
Cancer-associated mutation and beyond: The emerging biology of isocitrate
dehydrogenases in human disease. Sci Adv 5, eaaw4543 (2019).
5.
Cairns RA, Mak TW, Oncogenic isocitrate dehydrogenase mutations:
mechanisms, models, and clinical opportunities. Cancer Discov 3, 730-41
(2013).
6.
Waitkus MS, Diplas BH, Yan H, Biological Role and Therapeutic Potential of
IDH Mutations in Cancer. Cancer Cell 34, 186-95 (2018).
7.
Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P,
64
Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S,
Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA, Hartigan J, Smith
DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD,
Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE,
Kinzler KW, An integrated genomic analysis of human glioblastoma multiforme.
Science 321, 1807-12 (2008).
8.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, BatinicHaberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon
J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD, IDH1 and IDH2
mutations in gliomas. N Engl J Med 360, 765-73 (2009).
9.
Reitman ZJ, Yan H, Isocitrate dehydrogenase 1 and 2 mutations in cancer:
alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102, 93241 (2010).
10.
Losman JA, Kaelin WG, What a difference a hydroxyl makes: mutant IDH, (R)2-hydroxyglutarate, and cancer. Genes Dev 27, 836-52 (2013).
11.
M Gagné L, Boulay K, Topisirovic I, Huot M, Mallette FA, Oncogenic
Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. Trends
Cell Biol 27, 738-52 (2017).
12.
Clark O, Yen K, Mellinghoff IK, Molecular Pathways: Isocitrate
Dehydrogenase Mutations in Cancer. Clin Cancer Res 22, 1837-42 (2016).
13.
Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R,
65
O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn
PC, Futreal A, Tirabosco R, Flanagan AM, IDH1 and IDH2 mutations are
frequent events in central chondrosarcoma and central and periosteal
chondromas but not in other mesenchymal tumours. J Pathol 224, 334-43
(2011).
14.
Pansuriya TC, van Eijk R, d'Adamo P, van Ruler MA, Kuijjer ML, Oosting J,
Cleton-Jansen AM, van Oosterwijk JG, Verbeke SL, Meijer D, van Wezel T,
Nord KH, Sangiorgi L, Toker B, Liegl-Atzwanger B, San-Julian M, Sciot R,
Limaye N, Kindblom LG, Daugaard S, Godfraind C, Boon LM, Vikkula M,
Kurek KC, Szuhai K, French PJ, Bovée JV, Somatic mosaic IDH1 and IDH2
mutations are associated with enchondroma and spindle cell hemangioma in
Ollier disease and Maffucci syndrome. Nat Genet 43, 1256-61 (2011).
15.
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt
DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini
VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM,
Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF,
Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK,
Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME,
Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH,
Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ,
Graubert TA, DiPersio JF, Wilson RK, Ley TJ, Recurring mutations found by
66
sequencing an acute myeloid leukemia genome. N Engl J Med 361, 1058-66
(2009).
16.
Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR,
Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA,
Levine RL, Thompson CB, The common feature of leukemia-associated IDH1
and IDH2 mutations is a neomorphic enzyme activity converting alphaketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225-34 (2010).
17.
Ohgaki H, Kleihues P, The definition of primary and secondary glioblastoma.
Clin Cancer Res 19, 764-72 (2013).
18.
Mondesir J, Willekens C, Touat M, de Botton S, IDH1 and IDH2 mutations as
novel therapeutic targets: current perspectives. J Blood Med 7, 171-80 (2016).
19.
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J,
Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken
JW, Wesseling P, Reifenberger G, von Deimling A, Type and frequency of IDH1
and IDH2 mutations are related to astrocytic and oligodendroglial differentiation
and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118, 469-74 (2009).
20.
Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE, Boyiadzis M,
DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid
malignancies: associations with prognosis and potential treatment strategies.
Leukemia 28, 1774-83 (2014).
21.
Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Wu
67
SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo KT, Lee FY, Liu MC, Liu
CW, Tseng MH, Huang CF, Tien HF, The prognostic impact and stability of
Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid
leukemia. Leukemia 25, 246-53 (2011).
22.
Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A,
van Putten WJ, Rijneveld AW, Löwenberg B, Valk PJ, Acquired mutations in the
genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid
leukemia: prevalence and prognostic value. Blood 116, 2122-6 (2010).
23.
Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein
DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP,
Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ, Frequent
mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma
identified through broad-based tumor genotyping. Oncologist 17, 72-9 (2012).
24.
Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W,
Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone
SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye
D, Guan KL, Xiong Y, Qin LX, Chiang DY, Mutations in isocitrate
dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas
and share hypermethylation targets with glioblastomas. Oncogene 32, 3091-100
(2013).
25.
Grassian AR, Pagliarini R, Chiang DY, Mutations of isocitrate dehydrogenase 1
68
and 2 in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 30, 295-302
(2014).
26.
Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith
WE, Zhang J, Roberts LR, Gores GJ, Halling KC, Isocitrate dehydrogenase 1
and 2 mutations in cholangiocarcinoma. Hum Pathol 43, 1552-8 (2012).
27.
Zou S, Li J, Zhou H, Frech C, Jiang X, Chu JS, Zhao X, Li Y, Li Q, Wang H,
Hu J, Kong G, Wu M, Ding C, Chen N, Hu H, Mutational landscape of
intrahepatic cholangiocarcinoma. Nat Commun 5, 5696 (2014).
28.
Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N,
Guthrie VB, Maitra A, Argani P, Offerhaus GJA, Roa JC, Roberts LR, Gores GJ,
Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A,
Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, de Braud F, Scarpa
A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein
B, Kinzler KW, Papadopoulos N, Wood LD, Exome sequencing identifies
frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic
cholangiocarcinomas. Nat Genet 45, 1470-3 (2013).
29.
Al-Khallaf H, Isocitrate dehydrogenases in physiology and cancer: biochemical
and molecular insight. Cell Biosci 7, 37 (2017).
30.
Gupta R, Flanagan S, Li CC, Lee M, Shivalingham B, Maleki S, Wheeler HR,
Buckland ME, Expanding the spectrum of IDH1 mutations in gliomas. Mod
Pathol 26, 619-25 (2013).
69
31.
Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D,
Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL,
Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson
RA, Bloomfield CD, IDH1 and IDH2 gene mutations identify novel molecular
subsets within de novo cytogenetically normal acute myeloid leukemia: a
Cancer and Leukemia Group B study. J Clin Oncol 28, 2348-55 (2010).
32.
Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR,
Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL,
Chan TA, Levine RL, Mellinghoff IK, Thompson CB, IDH mutation impairs
histone demethylation and results in a block to cell differentiation. Nature 483,
474-8 (2012).
33.
Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat
N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters
JK, Liu W, Choe SE, Fantin VR, Paietta E, Löwenberg B, Licht JD, Godley LA,
Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A, Leukemic IDH1 and
IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function,
and impair hematopoietic differentiation. Cancer Cell 18, 553-67 (2010).
34.
Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H,
Liu Y, Sundaram RK, Hegan DC, Fons NR, Breuer GA, Song Y, Mishra-Gorur
K, De Feyter HM, de Graaf RA, Surovtseva YV, Kachman M, Halene S, Günel
M, Glazer PM, Bindra RS, 2-Hydroxyglutarate produced by neomorphic IDH
70
mutations suppresses homologous recombination and induces PARP inhibitor
sensitivity. Sci Transl Med 9, (2017).
35.
Molenaar RJ, Radivoyevitch T, Maciejewski JP, van Noorden CJ, Bleeker FE,
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations
in oncogenesis and survival prolongation. Biochim Biophys Acta 1846, 326-41
(2014).
36.
Han S, Liu Y, Cai SJ, Qian M, Ding J, Larion M, Gilbert MR, Yang C, IDH
mutation in glioma: molecular mechanisms and potential therapeutic targets. Br
J Cancer 122, 1580-9 (2020).
37.
Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu
LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY,
Guan KL, Zhao SM, Xiong Y, Oncometabolite 2-hydroxyglutarate is a
competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell
19, 17-30 (2011).
38.
Prensner JR, Chinnaiyan AM, Metabolism unhinged: IDH mutations in cancer.
Nat Med 17, 291-3 (2011).
39.
Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung
IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ,
Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A, The oncometabolite 2hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12, 463-9
(2011).
71
40.
Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, Hama N,
Hosoda F, Urushidate T, Ohashi S, Hiraoka N, Ojima H, Shimada K, Okusaka T,
Kosuge T, Miyagawa S, Shibata T, Genomic spectra of biliary tract cancer. Nat
Genet 47, 1003-10 (2015).
41.
Blechacz B, Cholangiocarcinoma: Current Knowledge and New Developments.
Gut Liver 11, 13-26 (2017).
42.
Hoyos S, Navas MC, Restrepo JC, Botero RC, Current controversies in
cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 1864, 1461-7 (2018).
43.
Razumilava N, Gores GJ, Cholangiocarcinoma. Lancet 383, 2168-79 (2014).
44.
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ, Cholangiocarcinoma evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15, 95-111
(2018).
45.
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR,
Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ,
Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA,
Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P,
Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner
A, Bridgewater J, Valle JW, Gores GJ, Cholangiocarcinoma 2020: the next
horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 17,
557-88 (2020).
46.
Brown KM, Parmar AD, Geller DA, Intrahepatic cholangiocarcinoma. Surg
72
Oncol Clin N Am 23, 231-46 (2014).
47.
Buettner S, van Vugt JL, IJzermans JN, Groot Koerkamp B, Intrahepatic
cholangiocarcinoma: current perspectives. Onco Targets Ther 10, 1131-42
(2017).
48.
Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, Lee HJ, Sheehan
CE, Otto GA, Palmer G, Yelensky R, Lipson D, Morosini D, Hawryluk M,
Catenacci DV, Miller VA, Churi C, Ali S, Stephens PJ, New routes to targeted
therapy of intrahepatic cholangiocarcinomas revealed by next-generation
sequencing. Oncologist 19, 235-42 (2014).
49.
Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny
NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek
A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB,
Abou-Alfa GK, Comprehensive Molecular Profiling of Intrahepatic and
Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clin
Cancer Res 24, 4154-61 (2018).
50.
Lee K, Song YS, Shin Y, Wen X, Kim Y, Cho NY, Bae JM, Kang GH,
Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated
hypermethylation at selective genes and their clinicopathological features. Sci
Rep 10, 15820 (2020).
51.
Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW,
Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone
73
CR, Tanabe KK, Chong DQ, Deshpande V, Borger DR, Iafrate AJ, Bardeesy N,
Zheng H, Zhu AX, Prognosis and Clinicopathologic Features of Patients With
Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type
Intrahepatic Cholangiocarcinoma. Oncologist 20, 1019-27 (2015).
52.
Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl
RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu
I, Bauer TW, Gamblin TC, Gigot JF, Anders RA, Pawlik TM, Genomic profiling
of intrahepatic cholangiocarcinoma: refining prognosis and identifying
therapeutic targets. Ann Surg Oncol 21, 3827-34 (2014).
53.
Hanahan D, Weinberg RA, Hallmarks of cancer: the next generation. Cell 144,
646-74 (2011).
54.
Adekola K, Rosen ST, Shanmugam M, Glucose transporters in cancer
metabolism. Curr Opin Oncol 24, 650-4 (2012).
55.
Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A, Regulation of glut1
mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J
Biol Chem 276, 9519-25 (2001).
56.
Hayashi M, Sakata M, Takeda T, Yamamoto T, Okamoto Y, Sawada K, Kimura
A, Minekawa R, Tahara M, Tasaka K, Murata Y, Induction of glucose transporter
1 expression through hypoxia-inducible factor 1alpha under hypoxic conditions
in trophoblast-derived cells. J Endocrinol 183, 145-54 (2004).
57.
Wieman HL, Wofford JA, Rathmell JC, Cytokine stimulation promotes glucose
74
uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and
trafficking. Mol Biol Cell 18, 1437-46 (2007).
58.
Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ,
Rathmell JC, Glucose uptake is limiting in T cell activation and requires CD28mediated Akt-dependent and independent pathways. J Immunol 180, 4476-86
(2008).
59.
Fang J, Zhou SH, Fan J, Yan SX, Roles of glucose transporter-1 and the
phosphatidylinositol 3‑kinase/protein kinase B pathway in cancer radioresistance
(review). Mol Med Rep 11, 1573-81 (2015).
60.
Zhang Z, Yao L, Yang J, Wang Z, Du G, PI3K/Akt and HIF‑1 signaling pathway
in hypoxia‑ischemia (Review). Mol Med Rep 18, 3547-54 (2018).
61.
Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD,
Vilela RS, Paiva GR, Andrade RG, Soares FA, GLUT1 expression in malignant
tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 66, 96572 (2011).
62.
Zambrano A, Molt M, Uribe E, Salas M, Glut 1 in Cancer Cells and the
Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy. Int J Mol
Sci 20, (2019).
63.
Ancey PB, Contat C, Meylan E, Glucose transporters in cancer - from tumor
cells to the tumor microenvironment. FEBS J 285, 2926-43 (2018).
64.
Kubo Y, Aishima S, Tanaka Y, Shindo K, Mizuuchi Y, Abe K, Shirabe K,
75
Maehara Y, Honda H, Oda Y, Different expression of glucose transporters in the
progression of intrahepatic cholangiocarcinoma. Hum Pathol 45, 1610-7 (2014).
65.
Paudyal B, Oriuchi N, Paudyal P, Higuchi T, Nakajima T, Endo K, Expression
of glucose transporters and hexokinase II in cholangiocellular carcinoma
compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission
tomography. Cancer Sci 99, 260-6 (2008).
66.
Carbonneau M, M Gagné L, Lalonde ME, Germain MA, Motorina A, Guiot
MC, Secco B, Vincent EE, Tumber A, Hulea L, Bergeman J, Oppermann U,
Jones RG, Laplante M, Topisirovic I, Petrecca K, Huot M, Mallette FA, The
oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. Nat
Commun 7, 12700 (2016).
67.
Ikenoue T, Terakado Y, Nakagawa H, Hikiba Y, Fujii T, Matsubara D, Noguchi
R, Zhu C, Yamamoto K, Kudo Y, Asaoka Y, Yamaguchi K, Ijichi H, Tateishi K,
Fukushima N, Maeda S, Koike K, Furukawa Y, A novel mouse model of
intrahepatic cholangiocarcinoma induced by liver-specific Kras activation and
Pten deletion. Sci Rep 6, 23899 (2016).
68.
Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK,
Thompson CB, The potential for isocitrate dehydrogenase mutations to produce
2-hydroxyglutarate depends on allele specificity and subcellular
compartmentalization. J Biol Chem 288, 3804-15 (2013).
69.
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y,
76
Ding J, Lei Q, Guan KL, Xiong Y, Glioma-derived mutations in IDH1
dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324,
261-5 (2009).
70.
Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M,
May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP,
Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski
C, Stegh AH, Cancer-Associated IDH1 Promotes Growth and Resistance to
Targeted Therapies in the Absence of Mutation. Cell Rep 19, 1858-73 (2017).
71.
Su R, Dong L, Li C, Nachtergaele S, Wunderlich M, Qing Y, Deng X, Wang Y,
Weng X, Hu C, Yu M, Skibbe J, Dai Q, Zou D, Wu T, Yu K, Weng H, Huang H,
Ferchen K, Qin X, Zhang B, Qi J, Sasaki AT, Plas DR, Bradner JE, Wei M,
Marcucci G, Jiang X, Mulloy JC, Jin J, He C, Chen J, R-2HG Exhibits Antitumor Activity by Targeting FTO/m. Cell 172, 90-105.e23 (2018).
72.
Núñez FJ, Mendez FM, Kadiyala P, Alghamri MS, Savelieff MG, GarciaFabiani MB, Haase S, Koschmann C, Calinescu AA, Kamran N, Saxena M,
Patel R, Carney S, Guo MZ, Edwards M, Ljungman M, Qin T, Sartor MA,
Tagett R, Venneti S, Brosnan-Cashman J, Meeker A, Gorbunova V, Zhao L,
Kremer DM, Zhang L, Lyssiotis CA, Jones L, Herting CJ, Ross JL,
Hambardzumyan D, Hervey-Jumper S, Figueroa ME, Lowenstein PR, Castro
MG, IDH1-R132H acts as a tumor suppressor in glioma via epigenetic upregulation of the DNA damage response. Sci Transl Med 11, (2019).
77
73.
Bralten LB, Kloosterhof NK, Balvers R, Sacchetti A, Lapre L, Lamfers M,
Leenstra S, de Jonge H, Kros JM, Jansen EE, Struys EA, Jakobs C, Salomons
GS, Diks SH, Peppelenbosch M, Kremer A, Hoogenraad CC, Smitt PA, French
PJ, IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.
Ann Neurol 69, 455-63 (2011).
74.
Nie QM, Lin YY, Yang X, Shen L, Guo LM, Que SL, Li XX, Ge JW, Wang GS,
Xiong WH, Guo P, Qiu YM, IDH1R¹³²H decreases the proliferation of U87
glioma cells through upregulation of microRNA-128a. Mol Med Rep 12, 6695701 (2015).
75.
Cui D, Ren J, Shi J, Feng L, Wang K, Zeng T, Jin Y, Gao L, R132H mutation in
IDH1 gene reduces proliferation, cell survival and invasion of human glioma by
downregulating Wnt/β-catenin signaling. Int J Biochem Cell Biol 73, 72-81
(2016).
76.
Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D,
Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von
Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler
B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M,
Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon
N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun
J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill
DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A,
78
Wick W, Platten M, Suppression of antitumor T cell immunity by the
oncometabolite (R)-2-hydroxyglutarate. Nat Med 24, 1192-203 (2018).
77.
Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L,
Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, Faull KF,
Jiang M, Clarke SG, Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung
ME, Reue K, Huang J, 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR
Signaling. Cell Metab 22, 508-15 (2015).
78.
Hashemi Goradel N, Najafi M, Salehi E, Farhood B, Mortezaee K,
Cyclooxygenase-2 in cancer: A review. J Cell Physiol 234, 5683-99 (2019).
79.
Liu B, Qu L, Yan S, Cyclooxygenase-2 promotes tumor growth and suppresses
tumor immunity. Cancer Cell Int 15, 106 (2015).
80.
Garg M, Braunstein G, Koeffler HP, LAMC2 as a therapeutic target for cancers.
Expert Opin Ther Targets 18, 979-82 (2014).
81.
Moon YW, Rao G, Kim JJ, Shim HS, Park KS, An SS, Kim B, Steeg PS,
Sarfaraz S, Changwoo Lee L, Voeller D, Choi EY, Luo J, Palmieri D, Chung
HC, Kim JH, Wang Y, Giaccone G, LAMC2 enhances the metastatic potential of
lung adenocarcinoma. Cell Death Differ 22, 1341-52 (2015).
82.
Fujiwara H, Tateishi K, Misumi K, Hayashi A, Igarashi K, Kato H, Nakatsuka
T, Suzuki N, Yamamoto K, Kudo Y, Hayakawa Y, Nakagawa H, Tanaka Y, Ijichi
H, Kogure H, Nakai Y, Isayama H, Hasegawa K, Fukayama M, Soga T, Koike
K, Mutant IDH1 confers resistance to energy stress in normal biliary cells
79
through PFKP-induced aerobic glycolysis and AMPK activation. Sci Rep 9,
18859 (2019).
83.
Qing Y, Dong L, Gao L, Li C, Li Y, Han L, Prince E, Tan B, Deng X, Wetzel C,
Shen C, Gao M, Chen Z, Li W, Zhang B, Braas D, Ten Hoeve J, Sanchez GJ,
Chen H, Chan LN, Chen CW, Ann D, Jiang L, Muschen M, Marcucci G, Plas
DR, Li Z, Su R, Chen J, R-2-hydroxyglutarate attenuates aerobic glycolysis in
leukemia by targeting the FTO/m(6)A/PFKP/LDHB axis. Mol Cell
84.
(2021).
Liberti MV, Locasale JW, The Warburg Effect: How Does it Benefit Cancer
Cells? Trends Biochem Sci 41, 211-8 (2016).
85.
Lenting K, Khurshed M, Peeters TH, van den Heuvel CNAM, van Lith SAM,
de Bitter T, Hendriks W, Span PN, Molenaar RJ, Botman D, Verrijp K,
Heerschap A, Ter Laan M, Kusters B, van Ewijk A, Huynen MA, van Noorden
CJF, Leenders WPJ, Isocitrate dehydrogenase 1-mutated human gliomas depend
on lactate and glutamate to alleviate metabolic stress. FASEB J 33, 557-71
(2019).
86.
Yu Y, Liao M, Liu R, Chen J, Feng H, Fu Z, Overexpression of lactate
dehydrogenase-A in human intrahepatic cholangiocarcinoma: its implication for
treatment. World J Surg Oncol 12, 78 (2014).
87.
Thonsri U, Seubwai W, Waraasawapati S, Sawanyawisuth K,
Vaeteewoottacharn K, Boonmars T, Cha'on U, Overexpression of lactate
dehydrogenase A in cholangiocarcinoma is correlated with poor prognosis.
80
Histol Histopathol 32, 503-10 (2017).
88.
Siska PJ, van der Windt GJ, Kishton RJ, Cohen S, Eisner W, MacIver NJ, Kater
AP, Weinberg JB, Rathmell JC, Suppression of Glut1 and Glucose Metabolism
by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell
Leukemia. J Immunol 197, 2532-40 (2016).
89.
Hoxhaj G, Manning BD, The PI3K-AKT network at the interface of oncogenic
signalling and cancer metabolism. Nat Rev Cancer 20, 74-88 (2020).
90.
Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM, Thompson CB,
Akt-directed glucose metabolism can prevent Bax conformation change and
promote growth factor-independent survival. Mol Cell Biol 23, 7315-28 (2003).
91.
Barthel A, Okino ST, Liao J, Nakatani K, Li J, Whitlock JP, Roth RA,
Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J
Biol Chem 274, 20281-6 (1999).
92.
Plas DR, Talapatra S, Edinger AL, Rathmell JC, Thompson CB, Akt and Bcl-xL
promote growth factor-independent survival through distinct effects on
mitochondrial physiology. J Biol Chem 276, 12041-8 (2001).
93.
Bruick RK, McKnight SL, A conserved family of prolyl-4-hydroxylases that
modify HIF. Science 294, 1337-40 (2001).
94.
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR,
Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton
DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ,
81
Ratcliffe PJ, C. elegans EGL-9 and mammalian homologs define a family of
dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
95.
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von
Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh
CW, Ratcliffe PJ, Targeting of HIF-alpha to the von Hippel-Lindau
ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 46872 (2001).
96.
Majmundar AJ, Wong WJ, Simon MC, Hypoxia-inducible factors and the
response to hypoxic stress. Mol Cell 40, 294-309 (2010).
97.
Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, Losman JA,
Joensuu P, Bergmann U, Gross S, Travins J, Weiss S, Looper R, Ligon KL,
Verhaak RG, Yan H, Kaelin WG, Transformation by the (R)-enantiomer of 2hydroxyglutarate linked to EGLN activation. Nature 483, 484-8 (2012).
98.
Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow
E, Ma Q, Gorski R, Cleaver S, Vander Heiden MG, MacKeigan JP, Finan PM,
Clish CB, Murphy LO, Manning BD, Activation of a metabolic gene regulatory
network downstream of mTOR complex 1. Mol Cell 39, 171-83 (2010).
99.
Tandon P, Gallo CA, Khatri S, Barger JF, Yepiskoposyan H, Plas DR,
Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and
apoptosis resistance induced by Pten deficiency. Proc Natl Acad Sci U S A 108,
2361-5 (2011).
82
100.
Dodd KM, Yang J, Shen MH, Sampson JR, Tee AR, mTORC1 drives HIF-1α
and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and
STAT3. Oncogene 34, 2239-50 (2015).
101.
He L, Gomes AP, Wang X, Yoon SO, Lee G, Nagiec MJ, Cho S, Chavez A,
Islam T, Yu Y, Asara JM, Kim BY, Blenis J, mTORC1 Promotes Metabolic
Reprogramming by the Suppression of GSK3-Dependent Foxk1
Phosphorylation. Mol Cell 70, 949-60.e4 (2018).
102.
Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia
AJ, Abraham RT, Regulation of hypoxia-inducible factor 1alpha expression and
function by the mammalian target of rapamycin. Mol Cell Biol 22, 7004-14
(2002).
103.
Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS,
Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C,
Deshpande V, Zhu AX, Hezel AF, Yen KE, Straley KS, Travins J, PopoviciMuller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S,
Bardeesy N, Mutant IDH inhibits HNF-4α to block hepatocyte differentiation
and promote biliary cancer. Nature 513, 110-4 (2014).
83
Acknowledgements
I would like to express my gratitude to all those who helped me writing this
thesis.
I gratefully acknowledge the help of my supervisor, Professor Yoichi Furukawa,
who has offered me valuable suggestions in the academic studies. Without his patient
instruction, insightful criticism and expert guidance, the completion of this thesis would
not have been possible.
I also gratefully acknowledge the help of my supervisor, Associate Professor
Tsuneo Ikenoue, who has given me so much advice and encouragement on my research
and this thesis.
I am also deeply indebted to Dr. Kiyoshi Yamaguchi, Seira Hatakeyama, Yumiko
Isobe, Rika Koubo and the laboratory members in Division of Clinical Genome Research,
The Institute of Medical Science, The University of Tokyo, for their kind help and
encouragement to me during my research.
Finally, I should express my very profound gratitude to my family for giving me
unfailing support and continuous encouragement throughout my years of study and
through the process of writing this thesis.
84
...
論文の公開元へ
